Repligen (NASDAQ:RGEN – Get Free Report) and Zura Bio (NASDAQ:ZURA – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.
Analyst Recommendations
This is a summary of current ratings for Repligen and Zura Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Repligen | 0 | 5 | 8 | 0 | 2.62 |
| Zura Bio | 0 | 1 | 5 | 1 | 3.00 |
Repligen currently has a consensus target price of $185.20, suggesting a potential upside of 19.59%. Zura Bio has a consensus target price of $15.80, suggesting a potential upside of 631.48%. Given Zura Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Zura Bio is more favorable than Repligen.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Repligen | $639.92 million | 13.56 | $35.60 million | ($0.37) | -418.54 |
| Zura Bio | N/A | N/A | -$69.24 million | N/A | N/A |
Repligen has higher revenue and earnings than Zura Bio.
Profitability
This table compares Repligen and Zura Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Repligen | -3.36% | 3.90% | 2.72% |
| Zura Bio | N/A | -37.36% | -29.81% |
Risk & Volatility
Repligen has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.04, suggesting that its stock price is 96% less volatile than the S&P 500.
Institutional & Insider Ownership
97.6% of Repligen shares are owned by institutional investors. Comparatively, 61.1% of Zura Bio shares are owned by institutional investors. 1.2% of Repligen shares are owned by insiders. Comparatively, 22.1% of Zura Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Repligen beats Zura Bio on 7 of the 12 factors compared between the two stocks.
About Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
About Zura Bio
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
